Robert J Soiffer

Robert J Soiffer

UNVERIFIED PROFILE

Are you Robert J Soiffer?   Register this Author

Register author
Robert J Soiffer

Robert J Soiffer

Publications by authors named "Robert J Soiffer"

Are you Robert J Soiffer?   Register this Author

100Publications

3790Reads

7Profile Views

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma.

Biol Blood Marrow Transplant 2019 Dec 5;25(12):2383-2387. Epub 2019 Aug 5.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Medical Oncology Division, University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.07.041DOI Listing
December 2019

Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 Oct 31. Epub 2019 Oct 31.

Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer, Institute, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.10.024DOI Listing
October 2019

Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation.

Authors:
Robert J Soiffer

Bone Marrow Transplant 2019 Aug;54(Suppl 2):798-802

Dana Farbcer Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0617-yDOI Listing
August 2019

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 01 3;25(1):137-144. Epub 2018 Aug 3.

Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.07.039DOI Listing
January 2019

Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis.

Biol Blood Marrow Transplant 2018 10 30;24(10):2164-2165. Epub 2018 Jun 30.

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.06.029DOI Listing
October 2018

Can IL-15 superagonist ALTer GVL?

Authors:
Robert J Soiffer

Blood 2018 06;131(23):2511-2512

Dana-Farber Cancer Institute.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-04-840835DOI Listing
June 2018

Reply to J.J. Boelens et al.

J Clin Oncol 2018 04 7;36(11):1176-1177. Epub 2018 Feb 7.

Robert J. Soiffer, Dana-Farber Cancer Institute, Boston, MA; Yi-Bin A. Chen, Massachusetts General Hospital, Boston, MA; and Madan H. Jagasia, Vanderbilt University Medical Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.2939DOI Listing
April 2018

Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation.

Blood 2018 03 22;131(10):1073-1080. Epub 2018 Jan 22.

Harvard Medical School, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-10-752154DOI Listing
March 2018

Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival.

Cancer Epidemiol Biomarkers Prev 2018 03 13;27(3):345-347. Epub 2018 Feb 13.

Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-17-1040DOI Listing
March 2018

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

J Clin Oncol 2017 Dec 17;35(36):4003-4011. Epub 2017 Oct 17.

Robert J. Soiffer, Haesook T. Kim, Vincent T. Ho, Edwin P. Alyea, and Jerome Ritz, Dana-Farber Cancer Institute; James D. Levine, Beth Israel Deaconess Medical Center and Harvard Medical School; Yi-Bin Chen, Massachusetts General Hospital, Boston; Frank Glavin, Neovii Biotech, Lexington, MA; Joseph McGuirk, University of Kansas Medical Center, Kansas City, KS; Mitchell E. Horwitz, Duke University Medical Center, Durham; Thomas C. Shea, University of North Carolina School of Medicine, Chapel Hill, NC; Laura Johnston, Stanford University, Stanford, CA; Mrinal M. Patnaik, Mayo Clinic, Rochester, MN; Witold Rybka, Penn State College of Medicine, Hershey; David L. Porter, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Andrew Artz, University of Chicago, Chicago; Patrick J. Stiff, Loyola University Medical Center, Maywood, IL; Michael W. Boyer, University of Utah, Salt Lake City, UT; Richard T. Maziarz, Oregon Health & Science University, Portland, OR; Paul J. Shaughnessy, Texas Transplant Institute, San Antonio; Madhuri Vusirikala, University of Texas Southwestern Medical Center, Dallas, TX; Usama Gergis, Weill Cornell Medical College; Ran Reshef, Columbia University Medical Center, New York, NY; Hana Safah, Tulane University, New Orleans, LA; John F. DiPersio and Peter Westervelt, Washington University School of Medicine, St Louis, MO; Jeff Szer, Royal Melbourne Hospital, Parkville, Victoria; Ian D. Lewis, Royal Adelaide Hospital, Adelaide, South Australia, Australia; Jennifer Holter, University of Oklahoma Health Sciences Center, Oklahoma City, OK; Paul J. Martin, Fred Hutchinson Cancer Research Center, Seattle, WA; Joseph A. Pidala, H. Lee Moffitt Cancer Center, Tampa, FL; and Madan H. Jagasia, Vanderbilt University Medical Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.8177DOI Listing
December 2017

Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):699-707

Harvard Medical School, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.699DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142540PMC
December 2017

Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Blood Adv 2017 Nov 28;1(25):2473-2482. Epub 2017 Nov 28.

Harvard Medical School, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017009894DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729623PMC
November 2017

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.

J Clin Oncol 2017 Sep 23;35(26):3002-3009. Epub 2017 Jun 23.

Asad Bashey, Melhem Solh, The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA; Mei-Jie Zhang, Andrew St. Martin, Trevor Argall, Mehdi Hamadani, and Mary Eapen, Medical College of Wisconsin, Milwaukee, WI; Shannon R. McCurdy and Ephraim Joseph Fuchs, The Johns Hopkins Hospital, Baltimore, MD; Claudio Anasetti, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Stefan O. Ciurea, MD Anderson Cancer Center, Houston, TX; Omotayo Fasan, The Center for Bone Marrow Transplantation at Geisinger Medical Center, Danville; Sameh Gaballa, Thomas Jefferson University Hospital, Philadelphia, PA; Pashna Munshi and Scott Rowley, MedStar Georgetown University Hospital, Washington, DC; Monzr M. Al Malki and Ryotaro Nakamura, City of Hope National Medical Center, Duarte, CA; Paul V. O'Donnell, Massachusetts General Hospital; Robert J. Soiffer, Dana-Farber Cancer Institute, Boston, MA; Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center, New York, NY; Kavita Raj, King's College Hospital, London; Vanderson Rocha, Churchill Hospital, Oxford, United Kingdom; Rizwan Romee, Barnes Jewish Hospital, St Louis, MO; Scott Rowley, Hackensack University Medical Center, Hackensack, NJ; and Rachel B. Salit, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.8428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590802PMC
September 2017

Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation.

Oral Surg Oral Med Oral Pathol Oral Radiol 2017 Sep 16;124(3):253-260. Epub 2017 Jun 16.

Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, USA; Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oooo.2017.06.003DOI Listing
September 2017

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.

J Clin Oncol 2017 May 9;35(14):1598-1605. Epub 2017 Jan 9.

Christopher J. Gibson, R. Coleman Lindsley, Brenton G. Mar, Jiantao Shi, Ann S. Lacasce, Arnold S. Freedman, David C. Fisher, Eric Jacobsen, Philippe Armand, Edwin P. Alyea, John Koreth, Vincent Ho, Robert J. Soiffer, Joseph H. Antin, Jerome Ritz, Sarah Nikiforow, Franziska Michor, and Donna Neuberg, Dana-Farber Cancer Institute; Jiantao Shi and Franziska Michor, Harvard T.H. Chan School of Public Health; Siddhartha Jaiswal, Elizabeth A. Morgan, and Benjamin L. Ebert, Brigham and Women's Hospital, Boston; Benjamin L. Ebert, Broad Institute, Cambridge, MA; Vatche Tchekmedyian, Memorial Sloan Kettering Cancer Center, New York, NY; Alysia Bosworth, Anita Bansal, and Stephen J. Forman, City of Hope National Medical Center, Duarte, CA; and Liton Francisco, Jianbo He, Ravi Bhatia, and Smita Bhatia, University of Alabama at Birmingham, Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.6712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455707PMC
May 2017

Continuation of a Levonorgestrel Intrauterine Device During Hematopoietic Stem Cell Transplant: A Case Report.

Anticancer Res 2017 04;37(4):1985-1987

Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.11541DOI Listing
April 2017

Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival.

Biol Blood Marrow Transplant 2017 01 24;23(1):113-118. Epub 2016 Oct 24.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.10.012DOI Listing
January 2017

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.

Haematologica 2016 10 27;101(10):1251-1259. Epub 2016 Jun 27.

Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.141176DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046655PMC
October 2016

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.

Biol Blood Marrow Transplant 2016 10 25;22(10):1808-1815. Epub 2016 Jul 25.

Department of Hematology, Instituto de Biomedicina de Sevilla (IBIS)/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.07.006DOI Listing
October 2016

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

N Engl J Med 2016 Jul;375(2):143-53

From the Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School (M.S.D., H.T.K., P.B., R.L., A.S., A.P.L., M.H., M.S., F.S.H., C.J.W., V.T.H., C. Cutler, J.K., E.P.A., J.H.A., P.A., J.R., R.J.S.), the Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center and Harvard Medical School (D.A.), the Bone Marrow Transplant Program, Massachusetts General Hospital Cancer Center and Harvard Medical School (Y.-B.C.), the Departments of Dermatology (N.R.L.) and Pathology (S.R.G., J.L.H., S.J.R.), Dana-Farber and Brigham and Women's Cancer Center, and the Dana-Farber Cancer Institute, Center for Molecular Oncologic Pathology (M.B., C.W.Z.) - all in Boston; Broad Institute of Massachusetts Institute of Technology and Harvard (P.B., C.J.W.) and Neon Therapeutics (M.S.R.) - both in Cambridge; the Blood and Marrow Transplant Program, University of California, San Diego, Moores Cancer Center, La Jolla (C. Costello, E.D.B.); Colorado Blood Cancer Institute, Denver (P.M.); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (H.S.); and the Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta (A.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1601202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149459PMC
July 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 07 11;30(1):183. Epub 2016 Jul 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.008DOI Listing
July 2016

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.

Biol Blood Marrow Transplant 2016 May 31;22(5):910-8. Epub 2015 Dec 31.

Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.12.024DOI Listing
May 2016

Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.

Blood 2016 05 4;127(20):2489-97. Epub 2016 Mar 4.

Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-12-688895DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874229PMC
May 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 04;29(4):574-586

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177991PMC
April 2016

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

Blood 2016 Feb 15;127(5):646-57. Epub 2015 Dec 15.

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-10-672345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742552PMC
February 2016

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.

J Clin Oncol 2015 Dec 2;33(35):4167-75. Epub 2015 Nov 2.

Steven M. Devine and William Blum, Ohio State University, Columbus, OH; Kouros Owzar, Flora Mulkey, Vera Hars, and Alexander B. Sibley, Alliance Statistics and Data Center, Duke University, Durham; Thomas C. Shea, University of North Carolina, Chapel Hill, NC; Richard M. Stone, Robert J. Soiffer, and Edwin P. Alyea, Dana-Farber Cancer Institute; Yi-Bin Chen, Massachusetts General Hospital, Boston, MA; Jack W. Hsu, University of Florida, Gainesville, FL; Richard E. Champlin, MD Anderson Cancer Research Center, Houston, TX; Ravi Vij, Washington University, St. Louis, MO; James Slack, Mayo Clinic, Scottsdale, AZ; Richard A. Larson, University of Chicago, Chicago, IL; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Shelly Carter, The EMMES Corporation, Bethesda, MD; Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; and Charles Linker, University of California at San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.7273DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658453PMC
December 2015

Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.

Biol Blood Marrow Transplant 2015 May 23;21(5):873-80. Epub 2015 Jan 23.

Department of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.01.019DOI Listing
May 2015

Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival.

Biol Blood Marrow Transplant 2015 Mar 5;21(3):509-16. Epub 2014 Dec 5.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.11.682DOI Listing
March 2015

Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.

Clin Cancer Res 2015 Mar 23;21(5):1010-8. Epub 2014 Dec 23.

Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1956DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348150PMC
March 2015

Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.

J Clin Oncol 2015 Feb 22;33(4):364-9. Epub 2014 Dec 22.

Mary Eapen, Brent R. Logan, Mary M. Horowitz, and Xiaobo Zhong, Medical College of Wisconsin, Milwaukee, WI; Miguel-Angel Perales, Memorial Sloan-Kettering Cancer Center, New York, NY; Stephanie J. Lee, Fred Hutchinson Cancer Research Center, Seattle, WA; Vanderson Rocha, Churchill Hospital, Oxford, United Kingdom; Robert J. Soiffer, Dana-Farber Cancer Institute, Boston, MA; and Richard E. Champlin, MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.2446DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302216PMC
February 2015

The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT.

J Natl Compr Canc Netw 2015 Feb;13(2):184-9

From the Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, and Department of Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0027DOI Listing
February 2015

Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.

Am J Hematol 2014 Dec 27;89(12):1092-6. Epub 2014 Aug 27.

Department of Medical Oncology/Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23825DOI Listing
December 2014

A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.

Biol Blood Marrow Transplant 2014 Nov 10;20(11):1737-43. Epub 2014 Jul 10.

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.06.040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465759PMC
November 2014

Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.

Haematologica 2014 Sep 23;99(9):1499-508. Epub 2014 May 23.

Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Boston, MA, USA Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Stem Cell Institute, Boston, MA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.104166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562540PMC
September 2014

White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.

Am J Hematol 2014 Jun 3;89(6):591-7. Epub 2014 Mar 3.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.23695
Publisher Site
http://dx.doi.org/10.1002/ajh.23695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031274PMC
June 2014

BK virus disease after allogeneic stem cell transplantation: a cohort analysis.

Biol Blood Marrow Transplant 2014 Apr 22;20(4):564-70. Epub 2014 Jan 22.

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts; Division of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.01.014DOI Listing
April 2014

Isavuconazole treatment of a patient with disseminated mucormycosis.

J Clin Microbiol 2014 Mar 8;52(3):1016-9. Epub 2014 Jan 8.

Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/JCM.03176-13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3957744PMC
March 2014

Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients.

Biol Blood Marrow Transplant 2014 Feb 22;20(2):285-7. Epub 2013 Nov 22.

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.11.013DOI Listing
February 2014

Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant 2013 Dec 27;19(12):1713-8. Epub 2013 Sep 27.

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.09.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848699PMC
December 2013

Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical center.

J Oncol Pract 2013 Sep 11;9(5):e228-33. Epub 2013 Jun 11.

Dana-Farber Cancer Institute; and Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2012.000841DOI Listing
September 2013